...
首页> 外文期刊>Cytometry, Part A: the journal of the International Society for Analytical Cytology >A Novel and Easy FxCycle (TM) Violet Based Flow Cytometric Method for Simultaneous Assessment of DNA Ploidy and Six-Color Immunophenotyping
【24h】

A Novel and Easy FxCycle (TM) Violet Based Flow Cytometric Method for Simultaneous Assessment of DNA Ploidy and Six-Color Immunophenotyping

机译:一种新颖且简便的基于FxCycle(TM)紫罗兰的流式细胞术,可同时评估DNA倍性和六色免疫分型

获取原文
获取原文并翻译 | 示例
           

摘要

Abnormal DNA ploidy is a valuable prognostic factor in many neoplasms, especially in hematological neoplasms like B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). Current methods of flow-cytometric (FC) DNA-ploidy evaluation are either technically difficult or limited to three- to four-color immunophenotyping and hence, challenging to evaluate DNA-ploidy in minute tumor population with background rich of its normal counterpart cells and other hematopoietic cells. We standardized a novel sensitive and easy method of simultaneous evaluation of six- to seven-color immunophenotyping and DNA-ploidy using a dye-FxCycle Violet (FCV). Linearity, resolution, and coefficient of variation (CV) for FCV were studied using chicken erythrocyte nuclei. Ploidy results of FCV were compared with Propidium iodide (PI) in 20 samples and intra-assay variation for FCV was studied. Using this six-color immunophenotyping & FCV-protocol DNA-ploidy was determined in bone-marrow samples from 124 B-ALL & 50 MM patients. Dilution experiment was also conducted to determine the sensitivity in detection of aneuploidy in minute tumor population. FCV revealed high linearity and resolution in 450/50 channel. On comparison with PI, CV of Go/G1-peak with FCV (mean-CV 4.1%) was slightly higher than PI (mean-CV 2.9%) but had complete agreement in ploidy results. Dilution experiment showed that aneuploidy could be accurately detected up to the limit of 0.01% tumor cells. Intra-assay variation was very low with CV of 0.005%. In B-ALL, hypodiploidy was noted in 4%, hyperdiploidy in 24%, near-hyperdiploidy in 13% and remaining 59% were diploid. In MM, hypodiploidy was in 2%, hyperdiploidy in 58%, near-hyperdiploidy in 8% and remaining 30% were diploid. FCV-based DNA-ploidy method is a sensitive and easy method for simultaneous evaluation of six-color immunophenotyping and DNA analysis. It is useful in DNA-ploidy evaluation of minute tumor population in cases like minimal residual disease and MM precursor conditions. (C) 2015 International Society for Advancement of Cytometry
机译:DNA倍体异常是许多肿瘤的重要预后因素,尤其是血液肿瘤如B细胞急性淋巴细胞白血病(B-ALL)和多发性骨髓瘤(MM)。当前的流式细胞术(FC)DNA倍性评估方法在技术上很困难或仅限于三色至四色免疫表型,因此,在背景丰富的正常对应细胞和其他背景下的微小肿瘤人群中评估DNA倍性具有挑战性造血细胞。我们使用染料FxCycle紫罗兰(FCV)标准化了一种新颖,灵敏,简便的方法,可同时评估六色至七色免疫表型和DNA倍性。使用鸡红细胞核研究了FCV的线性,分辨率和变异系数(CV)。将FCV的倍性结果与碘化丙啶(PI)在20个样品中进行了比较,并研究了FCV的批内分析方法。使用这种六色免疫表型和FCV方案,在124名B-ALL和50 MM患者的骨髓样本中确定了DNA倍性。还进行了稀释实验以确定在微小肿瘤群体中检测非整倍性的敏感性。 FCV在450/50通道中显示出高线性度和分辨率。与PI相比,Go / G1峰与FCV的CV(平均值CV为4.1%)略高于PI(平均值CV 2.9%),但在倍性结果上完全一致。稀释实验表明,在不超过0.01%肿瘤细胞的限度内,可以准确检测到非整倍性。测定内变异非常低,CV为0.005%。在B-ALL中,二倍体占4%,超二倍体占24%,近二倍体占13%,其余59%是二倍体。在MM中,二倍体占2%,超二倍体占58%,近二倍体占8%,其余30%为二倍体。基于FCV的DNA倍性方法是一种灵敏且简便的方法,可同时评估六色免疫表型和DNA分析。在最小残留病和MM前体疾病等情况下,它可用于微小肿瘤群体的DNA倍性评估。 (C)2015国际细胞计数学会

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号